medigraphic.com

2015, Número 2

<< Anterior Siguiente >>

Rev Educ Bioquimica 2015; 34 (2)


El papel de las plaquetas en enfermedades autoinmunes

Ramirez-Cruz NE, Ilescas I, Gallegos B, Solorzano C, Perez Y, Hernández CP

Idioma: Español
Referencias bibliográficas: 48
Paginas: 49-58
Archivo PDF: 524.96 Kb.


RESUMEN

Las plaquetas, son pequeñas células anucleadas, derivadas de los megacariocitos dentro de la médula ósea, juegan un papel vital en la respuesta hemostática normal al daño endotelial y son elementos clave en el Accidente Vascular Cerebral y el Infarto de miocardio. Las plaquetas tienen un papel importante en la modulación de la respuesta inmune innata ya que poseen actividad fagocítica y antibacteriana rudimentaria y en la respuesta inmune adaptativa, además de que contienen citocinas proinflamatorias como la IL-1, de esta manera modula la respuesta inmune e inflamatoria. En artritis reumatoide las plaquetas y las micropartículas derivadas de las plaquetas pueden acumularse en las articulaciones de los pacientes con artritis reumatoide, además de que las plaquetas pueden ser esenciales para la progresión de artritis inflamatoria. En lupus eritematoso sistémico, existe un aumento de reactividad de las plaquetas y el aumento de suero CD40L en pacientes con lupus eritematoso sistémico. En esclerosis sistémicas, las plaquetas están activadas en esta enfermedad. En esta revisión se presenta una visión general sobre el papel de las plaquetas en enfermedades autoinmunes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Thon JN, Montalvo A, Patel-Hett S, Devine MT, Richardson JL, EhrlicherA,Larson MK, Hoffmeister K, Hartwig JH, Italiano JE Jr (2010) Cytoskeletal mechanics of proplatelet maturation and platelet release. J Cell Biol 191:861-74.

  2. Italiano J E, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL (2008) Angiogenesis is regulated by a novel mechanism: pro and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 11:1227-33.

  3. Sehgal S, Storrie B (2007) Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost 5: 2009-16.

  4. Blair P, Flaumenhaft R (2009) Platelet alphagranules: basic biology and clinical correlates. Blood Rev 23: 177-89.

  5. Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E (2008) Platelets wound healing. Front Biosci 13: 3532-48.

  6. Semple W, Italiano JE, Freedman J (2011) Platelets and the immune continuum. Nat Rev Immunol 11:264–74.

  7. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, French PA, Dauerman HL, Becker RC (2009) Platelet Colloquium Participants. Platelet functions beyond hemostasis. J Thromb Haemost 7:1759–66.

  8. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestel FP, Ni H, Lazarus AH, Freedman J, Semple JW (2006) Platelet Toll-like receptor expression modulates lipopolysaccharideinduced thrombocytopenia and tumor necrosis factor-α production in vivo. Blood 107: 637–41.

  9. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD, Keys EM, Allen-Vercoe E, Devinney R, Doig CJ, Green FH, Kubes P (2007) Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13: 463–69.

  10. Zhang G, Han J, Welch EJ, Ye RD, Voyno- Yasenetskaya TA, Malik AB, Du X, Li Z (2009) Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol: 182:7997– 8004.

  11. Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ (2010) Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 115: 3632–39.

  12. Nurden AT (2011) Platelets, inflammation and tissue regeneration. Thromb Haemost 105:S13–33.

  13. Langer HF, Choi EY, Zhou H, Schleicher R, Chung KJ, Tang Z, Göbel K, Bdeir K, Chatzigeorgiou A, Wong C, Bhatia S, Kruhlak MJ, Rose JW, Burns JB, Hill KE, Qu H, Zhang Y, Lehrmann E, Becker KG, Wang Y, Simon DI, Nieswandt B, Lambris JD, Li X, Meuth SG, Kubes P, Chavakis T (2012) Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 110:1202–10.

  14. Lievens D, von Hundelshausen P (2011) Platelets in atherosclerosis. Thromb Haemost 106:827–38.

  15. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O’Donnell E, Farndale RW, Ware J, Lee DM (2010) Platelets amplify inflammation in arthritis via collagen- dependent microparticle production. Science 327:580–83.

  16. Grammer AC, Lipsky PE (2002) CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 46:1417–29.

  17. Ramirez GA, Franchini S, Rovere-Querini P, Sabbadini M G, Manfredi A A, Maugeri N (2012) The role of platelets in the pathogenesis of systemic sclerosis. Front Immunol 3:160 1-6.

  18. Senzel L, Gnatenko D V, Bahou W F (2009) The platelet proteome. Curr Opin Hematol16:329–33.

  19. Prahalad S, Martins TB, Tebo A E, Whiting A, Clifford B, Zeft AS, McNally B, Bohnsack JF, Hill HR (2008) Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis . Pediatr Rheumatol Online J 6:8.

  20. Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, Kuriyama M, Kipps T J, Hashimoto H (2001) Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 28:2583–90.

  21. Hamad O A, Nilsson P H, Wouters D, Lambris J D, Ekdahl K N, Nilsson B (2010) Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol 184:2686–92.

  22. Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B (2006) Blood platelets activate the classical pathway of human complement. J Thromb Haemost 4:2035–42.

  23. Tsuji M, Ezumi Y, Arai M, Takayama H (1997) A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem 272:23528–31.

  24. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808.

  25. Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N (2008) Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets 19: 146–54.

  26. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358: 903–11.

  27. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y (2010) PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 207:1853–62.

  28. Raijmakers R, van Beers JJ, El-Azzouny M, Visser NF, Bozic B, Pruijn GJ, Heck AJ (2012) Elevated levels of fibrinogen-derived endogenous citrullinated peptides in synovial fluid of rheumatoid arthritis patients. Arthritis Res Ther 14:R114.

  29. Knijff-Dutmer E A, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM , van de Laar M A (2002) Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 46:1498–503.

  30. Ertenli I, Kiraz S, Arici M, Haznedaroglu IC, Calguneri M, Celik I, Kirazli S (1998) P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol 25:1054–58.

  31. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97:2063–73.

  32. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI (2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46:1560–5.

  33. Mok CC, Wong CK, To CH, Lai JP, Lam CS (2011) Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebocontrolled trial. Arthritis Care Res (Hoboken) 63:875–83.

  34. Duffau P, Seneschal J, Nicco C, Richez C, Lazaro E, Douchet I, Bordes C, Viallard JF, Goulvestre C, Pellegrin J L, Weil B, Moreau J F, Batteux F, Blanco P (2010) Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med 2:47ra63.

  35. Gustafsson JT, Simard JF, Gunnarsson I, Elvin K, Lundberg IE, Hansson LO, Larsson A, Svenungsson E (2012) Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 14:R46.

  36. Pierangeli S S, Vega-Ostertag ME, Gonzalez E B (2007) New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol 9:1–15.

  37. Postlethwaite AE, Chiang TM (2007) Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 19:574–79.

  38. Maugeri N, Franchini S, Campana L, Baldini M, Ramirez GA, Sabbadini MG, Rovere-Querini P, Manfredi A A (2012) Circulating platelets as a source of the damage- associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity 45:584–7.

  39. Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S (2009) Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 29:180–9.

  40. Raucci A, Palumbo R, Bianchi M E (2007) HMGB1: a signal of necrosis. Autoimmunity 40:285–89.

  41. Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, Jüngel A, Beyer C, Krönke G, Zwerina J, Reiter R, Alenina N, Maroteaux L, Gay S, Schett G, Distler O, Distler JH (2011) Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 208:961–72.

  42. Truchetet M E, Allanore Y, Montanari E, Chizzolini C, Brembilla NC (2012) Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis. Ann Rheum Dis 71:2044–50.

  43. Christensen S, Farkas DK, Pedersen L, Miret M, Christiansen CF, Sorensen HT (2012) Multiple sclerosis and risk of venous thromboembolism: a population-based cohort study. Neuroepidemiology 38:76–83.

  44. Kihara Y, Ishii S, Kita Y, Toda A, Shimada A, Shimizu T (2005) Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J Exp Med 202:853– 63.

  45. Duerschmied D, Suidan G L, Demers M, Herr N, Carbo C, Brill A, Cifuni SM, Mauler M, Cicko S, Bader M, Idzko M, Bode C, Wagner DD (2012) Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 121:1008–15.

  46. Davalos D, Ryu J K, Merlini M, Baeten K M, Le Moan N, Petersen M A, Deerinck T J, Smirnoff D S, Bedard C, Hakozaki H, Gonias Murray S, Ling J B, Lassmann H, Degen J L, Ellisman M H, Akassoglou K (2012) Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 3:1227.

  47. Schachtrup C, Ryu J K, Helmrick M J, Vagena E, Galanakis D K, Degen J L, Margolis R U, Akassoglou K (2010) Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J Neurosci 30:5843–54.

  48. Projahn D, Koenen R (2012). Platelets: key players in vascular inflammation. J Leukoc Biol 92:1167–75.




2020     |     www.medigraphic.com